Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest retailer of ignoring warning signs that fraudsters used its money transfer ...

A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial ...

Among participants who were fully adherent to their regimen, mean weight loss was –22.7% in the CagriSema group, and 40.4% of participants assigned CagriSema who were fully adherent lost at ...

Additionally, a supportive secondary analysis showed that 50.7% of participants with obesity treated with CagriSema reached non-obesity levels (BMI 30 kg/m²) by the end of treatment, down from a mean ...

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.

CagriSema led to a 20.4% weight loss at 68 weeks vs. 3.0% with placebo in adults without diabetes. 50.7% of CagriSema users with obesity reached a BMI under 30, compared to 10.2% in the placebo ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

CagriSema is not approved in the US for weight loss. About the REDEFINE clinical trial program REDEFINE is a phase 3 clinical development program with once-weekly subcutaneous CagriSema in obesity.

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. CagriSema is not approved in the US for weight loss.

Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle ...